Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Molecular Profile||Indication/Tumor Type||Response Type||Relevant Treatment Approaches||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|FLT3 D835X||acute myeloid leukemia||sensitive||FLT3 Inhibitor||Crenolanib||Phase I||Actionable||In a Phase I trial, Crenolanib treatment resulted in an overall survival (OS) of 185 days in AML patients harboring FLT3 D835X that received no prior therapy (J Clin Oncol 34, 2016 (suppl; abstr 7008)).||detail...|
|FLT3 D835X||acute myeloid leukemia||sensitive||FLT3 Inhibitor||Selinexor + Sorafenib||Phase Ib/II||Actionable||In a Phase I/II trial, combination of Selinexor and Nexavar (sorafenib) treatment resulted in complete remission in 29% (4/14) and more than 50% blast reduction in 14% (2/14) of patients with acute myeloid leukemia harboring FLT3 ITD and/or D835 mutations (ASH, 59th Annual Meeting and Exposition, Dec 2017, Abstract 1344; NCT01607892).||detail...|
|FLT3 D835X||acute myeloid leukemia||sensitive||FLT3 Inhibitor||Cytarabine + Daunorubicin + Midostaurin||FDA approved - On Companion Diagnostic||Actionable||In a Phase III trial that supported FDA approval, treatment with Rydapt (midostaurin), combined with Cytosar-U (cytarabine) and Daunorubicin, improved overall survival (74.7 mo vs 25.6 mo) in patients with FLT3-mutant (D835X and I836X) or FLT3-ITD (exon 14 insertions) acute myeloid leukemia compared to Cytosar-U (cytarabine) and Daunorubicin with placebo (PMID: 28644114).||detail... 28644114 detail...|
|FLT3 D835X||acute myeloid leukemia||sensitive||FLT3 Inhibitor||Gilteritinib||FDA approved - On Companion Diagnostic||Actionable||In a Phase III trial (ADMIRAL) that supported FDA approval, Xospata (gilteritinib) treatment resulted in complete remission (CR) or CR with partial hematologic recovery in 21% (29/138) of patients with relapsed or refractory acute myeloid leukemia harboring a FLT3 internal tandem duplication (ITD), D835, or I836 mutation (FDA.gov; NCT02421939).||detail... detail...|
|FLT3 D835X||acute myeloid leukemia||predicted - sensitive||LAM-003||Preclinical - Patient cell culture||Actionable||In a preclinical study, patient-derived acute myeloid leukemia cells harboring FLT3 D835X demonstrated sensitivity to LAM-003 treatment in culture (PMID: 31751472).||31751472|
|FLT3 D835X||myelodysplastic syndrome||not applicable||N/A||Guideline||Prognostic||FLT3 D835 mutations are associated with poor prognosis in patients with myelodysplastic syndromes (NCCN.org).||detail...|